Oral kallidinogenase improved visual acuity and maintained chorioretinal blood flow levels after treatment for diabetic macular edema

Eiko Tsuiki,1 Kiyoshi Suzuma,2 Makiko Matsumoto,1 Yasser Helmy Mohamed,1 Takashi Kitaoka1 1Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan; 2Department of Ophthalmology and Visual Sciences, Kyoto University Graduate Schoo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tsuiki E, Suzuma K, Matsumoto M, Mohamed YH, Kitaoka T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Kallidinogenase Diabetic macular edema (DME) Laser speckle flowgraphy (LSFG) Enhanced depth imaging optical coherent tomography (EDI-OCT). Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/8899777d5fae40429c0fc7b64b74e6a2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8899777d5fae40429c0fc7b64b74e6a2
record_format	dspace
spelling	oai:doaj.org-article:8899777d5fae40429c0fc7b64b74e6a22021-12-02T05:37:29ZOral kallidinogenase improved visual acuity and maintained chorioretinal blood flow levels after treatment for diabetic macular edema1177-5483https://doaj.org/article/8899777d5fae40429c0fc7b64b74e6a22018-09-01T00:00:00Zhttps://www.dovepress.com/oral-kallidinogenase-improved-visual-acuity-and-maintained-chorioretin-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Eiko Tsuiki,1 Kiyoshi Suzuma,2 Makiko Matsumoto,1 Yasser Helmy Mohamed,1 Takashi Kitaoka1 1Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan; 2Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan Purpose: This study was designed to investigate the therapeutic effects of oral kallidinogenase medication as an adjuvant therapy in treating patients with diabetic macular edema (DME). Study design: This was a prospective, open-labeled, randomized study. Methods: All patients were given posterior sub-Tenon triamcinolone acetonide (STTA) injection and focal laser treatment session for DME. The patients were subdivided into two groups: 1) those treated with oral kallidinogenase for at least 6 months after local treatment (treated group) and 2) those treated without oral kallidinogenase (untreated group). In this study, best-corrected visual acuity (BCVA), central retinal thickness (CRT), subfoveal choroidal thickness (SCT), and chorioretinal blood flow level were measured in 17 patients (19 eyes). Chorioretinal blood flow levels at the disc and macula were measured by laser speckle flowgraphy and evaluated using the mean blur rate (MBR). These data were measured at baseline and at 1, 3, and 6 months after treatment initiation. Results: BCVA at 6 months after treatment significantly improved in treated group (P<0.05). But the mean CRT after treatment significantly decreased in both groups. There was no significant difference in the mean SCT at baseline between the two groups. The mean SCT after treatment in treated group was significantly thinner than that before treatment (P<0.05). Compared to baseline (100%), MBR at the disc and the macula at 6 months after treatment significantly decreased to 84.8% and 86.2%, respectively, in untreated group (P<0.05), though it remained unchanged at 98.7% and 99.7% in treated group. Conclusion: Oral kallidinogenase medication is useful as an adjuvant therapy to enhance the therapeutic effect of STTA in DME patients. Keywords: kallidinogenase, diabetic macular edema, laser speckle flowgraphy, enhanced depth imaging optical coherence tomographyTsuiki ESuzuma KMatsumoto MMohamed YHKitaoka TDove Medical PressarticleKallidinogenaseDiabetic macular edema (DME)Laser speckle flowgraphy (LSFG)Enhanced depth imaging optical coherent tomography (EDI-OCT).OphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 12, Pp 1845-1852 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Kallidinogenase Diabetic macular edema (DME) Laser speckle flowgraphy (LSFG) Enhanced depth imaging optical coherent tomography (EDI-OCT). Ophthalmology RE1-994
spellingShingle	Kallidinogenase Diabetic macular edema (DME) Laser speckle flowgraphy (LSFG) Enhanced depth imaging optical coherent tomography (EDI-OCT). Ophthalmology RE1-994 Tsuiki E Suzuma K Matsumoto M Mohamed YH Kitaoka T Oral kallidinogenase improved visual acuity and maintained chorioretinal blood flow levels after treatment for diabetic macular edema
description	Eiko Tsuiki,1 Kiyoshi Suzuma,2 Makiko Matsumoto,1 Yasser Helmy Mohamed,1 Takashi Kitaoka1 1Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan; 2Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan Purpose: This study was designed to investigate the therapeutic effects of oral kallidinogenase medication as an adjuvant therapy in treating patients with diabetic macular edema (DME). Study design: This was a prospective, open-labeled, randomized study. Methods: All patients were given posterior sub-Tenon triamcinolone acetonide (STTA) injection and focal laser treatment session for DME. The patients were subdivided into two groups: 1) those treated with oral kallidinogenase for at least 6 months after local treatment (treated group) and 2) those treated without oral kallidinogenase (untreated group). In this study, best-corrected visual acuity (BCVA), central retinal thickness (CRT), subfoveal choroidal thickness (SCT), and chorioretinal blood flow level were measured in 17 patients (19 eyes). Chorioretinal blood flow levels at the disc and macula were measured by laser speckle flowgraphy and evaluated using the mean blur rate (MBR). These data were measured at baseline and at 1, 3, and 6 months after treatment initiation. Results: BCVA at 6 months after treatment significantly improved in treated group (P<0.05). But the mean CRT after treatment significantly decreased in both groups. There was no significant difference in the mean SCT at baseline between the two groups. The mean SCT after treatment in treated group was significantly thinner than that before treatment (P<0.05). Compared to baseline (100%), MBR at the disc and the macula at 6 months after treatment significantly decreased to 84.8% and 86.2%, respectively, in untreated group (P<0.05), though it remained unchanged at 98.7% and 99.7% in treated group. Conclusion: Oral kallidinogenase medication is useful as an adjuvant therapy to enhance the therapeutic effect of STTA in DME patients. Keywords: kallidinogenase, diabetic macular edema, laser speckle flowgraphy, enhanced depth imaging optical coherence tomography
format	article
author	Tsuiki E Suzuma K Matsumoto M Mohamed YH Kitaoka T
author_facet	Tsuiki E Suzuma K Matsumoto M Mohamed YH Kitaoka T
author_sort	Tsuiki E
title	Oral kallidinogenase improved visual acuity and maintained chorioretinal blood flow levels after treatment for diabetic macular edema
title_short	Oral kallidinogenase improved visual acuity and maintained chorioretinal blood flow levels after treatment for diabetic macular edema
title_full	Oral kallidinogenase improved visual acuity and maintained chorioretinal blood flow levels after treatment for diabetic macular edema
title_fullStr	Oral kallidinogenase improved visual acuity and maintained chorioretinal blood flow levels after treatment for diabetic macular edema
title_full_unstemmed	Oral kallidinogenase improved visual acuity and maintained chorioretinal blood flow levels after treatment for diabetic macular edema
title_sort	oral kallidinogenase improved visual acuity and maintained chorioretinal blood flow levels after treatment for diabetic macular edema
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/8899777d5fae40429c0fc7b64b74e6a2
work_keys_str_mv	AT tsuikie oralkallidinogenaseimprovedvisualacuityandmaintainedchorioretinalbloodflowlevelsaftertreatmentfordiabeticmacularedema AT suzumak oralkallidinogenaseimprovedvisualacuityandmaintainedchorioretinalbloodflowlevelsaftertreatmentfordiabeticmacularedema AT matsumotom oralkallidinogenaseimprovedvisualacuityandmaintainedchorioretinalbloodflowlevelsaftertreatmentfordiabeticmacularedema AT mohamedyh oralkallidinogenaseimprovedvisualacuityandmaintainedchorioretinalbloodflowlevelsaftertreatmentfordiabeticmacularedema AT kitaokat oralkallidinogenaseimprovedvisualacuityandmaintainedchorioretinalbloodflowlevelsaftertreatmentfordiabeticmacularedema
_version_	1718400307249020928

Oral kallidinogenase improved visual acuity and maintained chorioretinal blood flow levels after treatment for diabetic macular edema

Ejemplares similares